Fruquintinib | List of Frontiers open access articles

Original Research

Published on 11 Mar 2025

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Qinqin Song
Hongjiao Wu
Ye Jin
Junzhi Hou
Jiawei Liu
Xuemei Zhang
Wanning Hu
Guogui Sun
Zhi Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1503133

3,532 views
4 citations

Original Research

Published on 16 Jul 2025

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

in Cancer Immunity and Immunotherapy

Yao Wang
Du Meilu
Shi Qi
Tang Yufei
Gao Song
Han Susu
Wen Haotian
Zhu Tingting
Wang Chao
Hou Fenggang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1582308

3,614 views

Original Research

Published on 17 Mar 2022

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

in Cancer Molecular Targets and Therapeutics

Qingli Li
Xiaojiao Cheng
Cong Zhou
Yao Tang
Fuli Li
Baiwen Zhang
Tinglei Huang
Jianzheng Wang
Shuiping Tu

Frontiers in Oncology

doi 10.3389/fonc.2022.841977

10,652 views
44 citations

Case Report

Published on 28 Jun 2023

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Ruiqi Wang
Dan Cong
Yuansong Bai
Wenlong Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1207369

4,695 views
2 citations

Original Research

Published on 03 Mar 2023

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

in Gastrointestinal Cancers: Colorectal Cancer

Ya-Ya Deng
Xin-Yue Zhang
Peng-Fei Zhu
Hong-Rui Lu
Qian Liu
Shuang-Yue Pan
Zhe-Ling Chen
Liu Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1097911

11,459 views
24 citations

Case Report

Published on 05 Jul 2021

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer

in Pharmacology of Anti-Cancer Drugs

Yefei Shu
Song Zheng

Frontiers in Oncology

doi 10.3389/fonc.2021.688231

4,342 views
2 citations

Original Research

Published on 11 Dec 2025

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations

in Cancer Immunity and Immunotherapy

Lucía Suárez
María Martínez-Azcona
Irantzu Serrano-Mendioroz
Leticia Fernández-Rubio
María Esperanza Rodríguez-Ruiz
Ana Rouzaut

Frontiers in Immunology

doi 10.3389/fimmu.2025.1699980

1,545 views

Original Research

Published on 24 Nov 2022

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer

in Gastrointestinal Cancers: Colorectal Cancer

Ying Jin
Jin Li
Lin Shen
Jianming Xu
Yanqiao Zhang
Jingdong Zhang
Hongming Pan
Xiujuan Qu
Yamin Chen
Qiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1044328

6,953 views
6 citations

Original Research

Published on 02 Dec 2024

A real-world study: third-line treatment options for metastatic colorectal cancer

in Molecular and Cellular Oncology

Chen Wu
Shuai Li
Xinfang Hou

Frontiers in Oncology

doi 10.3389/fonc.2024.1480704

5,731 views
2 citations

Original Research

Published on 13 Nov 2020

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

in Gastrointestinal Cancers

Lei Wang
Huijiao Cao
Chang Jiang
Wenzhuo He
Yafei You
Kunwei Peng
Yanan Jin
Liangping Xia

Frontiers in Oncology

doi 10.3389/fonc.2020.587692

4,468 views
5 citations

Original Research

Published on 26 Sep 2022

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

in Gastrointestinal Cancers: Colorectal Cancer

Caiyun Nie
Huifang Lv
Beibei Chen
Weifeng Xu
Jianzheng Wang
Yingjun Liu
Saiqi Wang
Jing Zhao
Yunduan He
Xiaobing Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.917353

6,074 views
21 citations

Case Report

Published on 17 Apr 2025

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

in Cancer Immunity and Immunotherapy

Jie Dong
Jinli Zhang
Hongming Pan
Chongwei Wang
Jin Sheng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1521828

4,884 views

Original Research

Published on 31 Aug 2022

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study

in Gastrointestinal Cancers: Colorectal Cancer

Weijie Zhang
Zhongyue Zhang
Shitong Lou
Donghui Li
Zhijun Ma
Lei Xue

Frontiers in Oncology

doi 10.3389/fonc.2022.929342

5,780 views
23 citations

Original Research

Published on 07 Jul 2022

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China

in Gastrointestinal Cancers: Colorectal Cancer

Miaomiao Gou
Niansong Qian
Yong Zhang
Huan Yan
Haiyan Si
Zhikuan Wang
Guanghai Dai

Frontiers in Oncology

doi 10.3389/fonc.2022.851756

8,044 views
36 citations

Systematic Review

Published on 09 Sep 2025

Efficacy and safety of fruquintinib in the treatment of colorectal cancer: a systematic review and meta-analysis of studies in China

in Gastrointestinal and Hepatic Pharmacology

Yuan Feng
Yu Shu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1590782

2,564 views

Original Research

Published on 20 Aug 2024

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy

in Cancer Imaging and Image-directed Interventions

Kanglian Zheng
Xu Zhu
Liang Xu
Guang Cao
Chuanxin Niu
Xiaoluan Yan
Da Xu
Wei Liu
Quan Bao
Lijun Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1420956

4,039 views
4 citations

Articles

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer

A real-world study: third-line treatment options for metastatic colorectal cancer

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China

Efficacy and safety of fruquintinib in the treatment of colorectal cancer: a systematic review and meta-analysis of studies in China

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy